Fractionation and protraction for radiotherapy of prostate carcinoma

International Journal of Radiation Oncology Biology Physics

Volumn 43, Issue 5, 1999, Pages 1095-1101

  Brenner, David J ^a   Hall, Eric J ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

HDR; Hypofractionation; Prostate cancer; Radiotherapy

Indexed keywords

ARTICLE; BRACHYTHERAPY; CANCER CONTROL; CANCER RADIOTHERAPY; CELL PROLIFERATION; PRIORITY JOURNAL; PROSTATE CARCINOMA; RADIATION DOSE; RADIATION DOSE DISTRIBUTION; RADIATION DOSE FRACTIONATION; RADIOSENSITIVITY; STATISTICAL MODEL;

BRACHYTHERAPY; DOSE FRACTIONATION; HUMANS; MALE; MODELS, BIOLOGICAL; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOBIOLOGY;

EID: 0032913909     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(98)00438-6     Document Type: Article

References (43)

1. Jones G.W., Mettlin C., Murphy G.P., et al. Patterns of care for carcinoma of the prostate gland Results of a national survey of 1984 and 1990 . J Am Coll Surg. 180:1995;545-554.
2. Zelefsky M.J., Leibel S.A., Kutcher G.J., et al. Three-dimensional conformal radiotherapy and dose escalation Where do we stand? Semin Radiat Oncol. 8:1998;107-114.
3. Nori D., Moni J. Current issues in techniques of prostate brachytherapy. Semin Surg Oncol. 13:1997;444-453.
4. 125I implantation . Int J Radiat Oncol Biol Phys. 21:1991;537-547.
5. Roach M. 3rd, Meehan S., Kroll S., et al. Radiotherapy for high grade clinically localized adenocarcinoma of the prostate. J Urol. 156:1996;1719-1723.
6. Pollack A., Zagars G.K. External beam radiotherapy dose response of prostate cancer. Int J Radiat Oncol Biol Phys. 39:1997;1011-1018.
7. Hanks G.E., Schultheiss T.E., Hanlon A.L., et al. Optimization of conformal radiation treatment of prostate cancer Report of a dose escalation study . Int J Radiat Oncol Biol Phys. 37:1997;543-550.
8. Stock R.G., Stone N.N., Tabert A., et al. A dose-response study for I-125 prostate implants. Int J Radiat Oncol Biol Phys. 41:1998;101-108.
9. Thames H.D. An 'incomplete-repair' model for survival after fractionated and continuous irradiations. Int J Radiat Biol. 47:1985;319-339.
10. Tucker S.L., Thames H.D., Taylor J.M. How well is the probability of tumor cure after fractionated irradiation described by Poisson statistics? Radiat Res. 124:1990;273-282.
11. Lea D.E., Catcheside D.G. The mechanism of the induction by radiation of chromosome aberrations in Tradescantia. J Genet. 44:1942;216-245.
12. Brenner D.J., Hlatky L.R., Hahnfeldt P.J., et al. The Linear-Quadratic model and most other common radiobiological models result in similar predictions for time-dose relationships. Radiat Res. 150:1998;1-9.
13. Dale R.G. The application of the linear-quadratic dose-effect equation to fractionated and protracted radiotherapy. Br J Radiol. 58:1985;515-528.
14. Brenner D.J., Huang Y., Hall E.J. Fractionated high dose-rate versus low dose-rate regimens for intracavitary brachytherapy of the cervix Equivalent regimens for combined brachytherapy and external irradiation . Int J Radiat Oncol Biol Phys. 21:1991;1415-1423.
15. Travis E.L., Tucker S.L. Isoeffect models and fractionated radiation therapy. Int J Radiat Oncol Biol Phys. 13:1987;283-287.
16. Fowler J.F., Ritter M.A. A rationale for fractionation for slowly proliferating tumors such as prostatic adenocarcinoma. Int J Radiat Oncol Biol Phys. 32:1995;521-529.
17. Haustermans K.M., Hofland I., Van Poppel H., et al. Cell kinetic measurements in prostate cancer. Int J Radiat Oncol Biol Phys. 37:1997;1067-1070.
18. Crook J.M., Choan E., Perry G.A., et al. Serum prostate-specific antigen profile following radiotherapy for prostate cancer Implications for patterns of failure and definition of cure . Urology. 51:1998;566-572.
19. Pollack A., Zagars G.K., Kavadi V.S. Prostate specific antigen doubling time and disease relapse after radiotherapy for prostate cancer. Cancer. 74:1994;670-678.
20. Dale R.G. Radiobiological assessment of permanent implants using tumour repopulation factors in the linear-quadratic model. Br J Radiol. 62:1989;241-244.
21. Lai P.P., Pilepich M.V., Krall J.M., et al. The effect of overall treatment time on the outcome of definitive radiotherapy for localized prostate carcinoma The Radiation Therapy Oncology Group 75-06 and 77-06 experience . Int J Radiat Oncol Biol Phys. 21:1991;925-933.
22. Brenner D.J. Dose volume and tumor-control predictions in radiotherapy. Int J Radiat Oncol Biol Phys. 26:1993;171-179.
23. Aihara M., Lebovitz R.M., Wheeler T.M., et al. Prostate specific antigen and Gleason grade An immunohistochemical study of prostate cancer . J Urol. 151:1994;1558-1564.
24. Kabalin J.N., McNeal J.E., Johnstone I.M., et al. Serum prostate-specific antigen and the biologic progression of prostate cancer. Urology. 46:1995;65-70.
25. Chan L.W., Stamey T.A. Calculating prostate cancer volume preoperatively The D'Amico equation and some other observations . J Urol. 159:1998;1998-2003.
26. Press W.H., Flanner B.P., Teukolsky S.A., et al. Numerical recipes. 1986;Cambridge University Press, Cambridge.
27. Pinover WH, Hanlon AL, Horowitz EM; et al. Defining the appropriate dose for prostate cancer patients with PSA < 10 ng/ml (abstract). Proceedings of 40th ASTRO Annual Meeting, Phoenix, AZ. 1998.
28. Thames H.D., Bentzen S.M., Turesson I., et al. Time-dose factors in radiotherapy A review of the human data . Radiother Oncol. 19:1990;219-235.
29. Bentzen S.M., Overgaard J., Thames H.D., et al. Clinical radiobiology of malignant melanoma. Radiother Oncol. 16:1989;169-182.
30. Thames H.D., Suit H.D. Tumor radioresponsiveness versus fractionation sensitivity. Int J Radiat Oncol Biol Phys. 12:1986;687-691.
31. Sasaki T., Sato Y., Sakka M. Cell population kinetics of human solid tumors A statistical analysis in various histological types . Gann. 71:1980;520-529.
32. Nordsmark M., Hoyer M., Keller J., et al. The relationship between tumor oxygenation and cell proliferation in human soft tissue sarcomas. Int J Radiat Oncol Biol Phys. 35:1996;701-708.
33. Scrivner D.L., Meyer J.S., Rujanavech N., et al. Cell kinetics by bromodeoxyuridine labeling and deoxyribonucleic acid ploidy in prostatic carcinoma needle biopsies. J Urol. 146:1991;1034-1039.
34. Deschavanne P.J., Malaise E.P. The relevance of alpha/beta ratios determined in vitro for human cell lines to the understanding of in vivo values. Int J Radiat Biol. 56:1989;539-542.
35. Suit H.D., Zietman A., Tomkinson K., et al. Radiation response of xenografts of a human squamous cell carcinoma and a glioblastoma multiforme A progress report . Int J Radiat Oncol Biol Phys. 18:1990;365-373.
36. Vegesna V., Withers H.R., Taylor J.M. Differential response of rapidly- and slowly-proliferating hair follicles of mice to fractionated irradiation. Int J Radiat Oncol Biol Phys. 17:1989;1027-1031.
37. Tucker S.L., Thames H.D., Brown B.W., et al. Direct analyses of in vivo colony survival after single and fractionated doses of radiation. Int J Radiat Biol. 59:1991;777-795.
38. Collins C.D., Lloyd-Davies R.W., Swan A.V. Radical external beam radiotherapy for localised carcinoma of the prostate using a hypofractionation technique. Clin Oncol ® Coll Radiol. 3:1991;127-132.
39. Bentzen S.M., Christensen J.J., Overgaard J., et al. Some methodological problems in estimating radiobiological parameters from clinical data Alpha/beta ratios and electron RBE for cutaneous reactions in patients treated with postmastectomy radiotherapy. Acta Oncol. 27:1988;105-116.
40. Ellis F. Letter The NSD concept and radioresistant tumours . Br J Radiol. 47:1974;909.
41. Hornsey S. The relationship between total dose number of fractions and fractions size in the response of malignant melanoma in patients. Br J Radiol. 51:1978;905-909.
42. Forman J.D., Duclos M., Shamsa F., et al. Hyperfractionated conformal radiotherapy in locally advanced prostate cancer Results of a dose escalation study . Int J Radiat Oncol Biol Phys. 34:1996;655-662.
43. Stromberg J., Martinez A., Gonzalez J., et al. Ultrasound-guided high dose rate conformal brachytherapy boost in prostate cancer Treatment description and preliminary results of a phase I/II clinical trial . Int J Radiat Oncol Biol Phys. 33:1995;161-171.